(-)-3-[4-[2-(2-ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (-)-3-[4-[2-(2-ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid
• 英文别名: 2-Ethoxy-3-[4-[2-(2-ethyl-4-oxoquinazolin-3-yl)ethoxy]phenyl]propanoic acid
• 化学式: C₂₃H₂₆N₂O₅
• 分子量: 410.47
• InChiKey: ZZLILCWINGFVAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  30
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  88.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  magnesium hydroxide 、 (-)-3-[4-[2-(2-ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid 以 异丙醇 为溶剂， 生成 (+/-)3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid magnesium salt
  参考文献：
  名称：

  Pharmaceutically acceptable salts of heterocyclic compounds

  摘要：

  本发明涉及通式（I）的药用可接受盐，它们的衍生物、类似物、互变异构体、立体异构体、多型体、药用可接受溶剂合物以及含有它们的药用可接受组合物。

  公开号：

  US20020169175A1

文献信息

• Pharmaceutically acceptable salts of heterocyclic compounds
  申请人：DR. REDDY'S LABORATORIES LTD.

  公开号：US20020169175A1

  公开（公告）日：2002-11-14

  The present invention relates to pharmaceutically acceptable salts of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. 1

  本发明涉及通式（I）的药用可接受盐，它们的衍生物、类似物、互变异构体、立体异构体、多型体、药用可接受溶剂合物以及含有它们的药用可接受组合物。
• NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP1073643B1

  公开（公告）日：2004-12-29
• SALTS OF PYRIMIDINE DERIVATIVES FOR USE AGAINST CORONARY HEART DISEASE AND ATHEROSCLEROSE
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP1363913A2

  公开（公告）日：2003-11-26
• [EN] NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES HETEROCYCLIQUES, LEUR UTILISATION EN MEDECINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：——

  公开号：WO1999008501A2

  公开（公告）日：1999-02-25

  [EN] The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel beta -aryl- alpha -oxysubstituted alkylcarboxylic acids of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
  [FR] L'invention concerne de nouveaux composés anti-obésité et hypocholestérolémiques, leurs dérivés, leurs analogues, leurs formes tautomères, leurs stéréoisomères, leurs polymorphes, leurs sels acceptables sur le plan pharmaceutique, leurs solvates acceptables sur le plan pharmaceutique et des compositions acceptables sur le plan pharmaceutique les contenant. Elle concerne, plus particulièrement, de nouveaux acides beta -aryl- alpha -oxysubstitué alkylcarboxyliques représentés par la formule (I), leurs dérivés, leurs analogues, leurs formes tautomères, leurs stéréoisomères, leurs polymorphes, leurs sels acceptables sur le plan pharmaceutique, leurs solvates acceptables sur le plan pharmaceutique et des compositions acceptables sur le plan pharmaceutique les contenant. (I)
• [EN] PHARMACEUTICALLY ACCEPTABLE SALTS OF HETEROCYCLIC COMPOUNDS<br/>[FR] SELS DE COMPOSES HETEROCYCLIQUES PHARMACEUTIQUEMENT ACCEPTABLES
  申请人：REDDY RESEARCH FOUNDATION

  公开号：WO2002062798A2

  公开（公告）日：2002-08-15

  The present invention relates to pharmaceutically acceptable salts of compound of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. The present invention relates to pharmaceutically acceptable salts of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs and pharmaceutically acceptable compositions containing them.